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The effects of ceftizoxime (CZX), piperacillin (PIP), and PIP-tazobactam (PT) concentrations on the anti-
bacterial activity and selection of resistant mutants of Bacteroides fragilis and Enterobacter cloacae were
investigated in vitro in a mixed-culture anaerobic time-kill study and in vivo in a mixed-infection abscess
model. Mixed cultures were incubated for 24 h with 0.125 to 512 g of CZX per ml or 0.125 to 2,048 g of PIP
or PT per ml. Mice were treated every 2 h for 24 h with CZX at 6 to 1,536 mg/kg/day or with PIP or PT at 24
to 6,144 mg/kg/day starting 30 min before inoculation with different B. fragilis-E. cloacae combinations. There
was a good correlation between the in vitro and in vivo activities of the antibiotics and their MICs obtained with
high inocula (108 CFU/ml). The respective 50% effective doses (milligrams per kilogram per day) with B. fragilis
and E. cloacae 22491 were 771 and 521 for CZX, 416 and 643 for PIP, and 85 and 554 for PT, and with the B.
fragilis-E. cloacae 032349 combination, they were 81 and 21 for CZX and 77 and 766 for PT. Resistant mutants
of E. cloacae 22491 were preferentially selected in vitro with 2 to 64 g of CZX per ml and in vivo with CZX
at 12 to 384 mg/kg/day. There was no preferential selection of CZX-resistant B. fragilis or E. cloacae 032349. For
CZX-resistant E. cloacae 22491, we found a 16- to 512-fold increase in the MIC of CZX and increased MICs
of other expanded-spectrum cephalosporins, owing in part to the production of a stably derepressed cepha-
losporinase. In vitro and in vivo, PT did not select resistant mutants of E. cloacae and B. fragilis. Results
demonstrate the adverse microbiological outcome of choosing an expanded-spectrum cephalosporin like CZX
for empirical treatment of mixed infections involving a susceptible Enterobacter strain.
Development of resistance in gram-negative bacteria during
-lactam therapy is a continuing dilemma (43) and can lead to
therapeutic failure (13), increased hospital stays and costs, and
increased mortality (5). The intensity of -lactam use is pro-
portional to the resistance levels of organisms isolated from
patients (25, 43), although differences in the ability of -lac-
tams to select these resistant strains during therapy have been
detected (9).
The most important mechanism of -lactam resistance in
Enterobacter and Bacteroides strains is the production of chro-
mosomally encoded -lactamases (10, 11). Most Bacteroides
fragilis enzymes are constitutive cephalosporinases or penicil-
linases that are inhibited by clavulanic acid (18), while the
chromosomally encoded cephalosporinases of Enterobacter
strains are inducible enzymes that are not inhibited by clavu-
lanic acid (11). The AmpC -lactamases of Enterobacter spp.
are normally produced at low basal levels. However, mutations
in the genes regulating the expression of these AmpC -lacta-
mases can cause stable derepression and constitutive produc-
tion of large amounts of cephalosporinase, resulting in mutant
strains that are resistant to expanded-spectrum cephalosporins
and aztreonam (17).
There have been very few in vivo studies that have investi-
gated the effects of antibiotic dosing regimens on the selection
of antimicrobial resistance during treatment (21). Expanded-
spectrum cephalosporins are more likely to select resistant
strains of Enterobacteriaceae than are other -lactams (23, 30,
35), while piperacillin (PIP)-tazobactam (TAZ) (the combina-
tion of PIP and TAZ is abbreviated PT) appears to suppress
the selection of derepressed mutants (20). Very little data are
available on the selection of -lactam resistance in B. fragilis
strains (10, 14, 18, 37).
The aim of the present study was to compare the effects of
a wide range of antibiotic doses of PIP and PT with those of the
expanded-spectrum cephalosporin ceftizoxime (CZX) on the
selection of antibiotic-resistant mutants of B. fragilis and En-
terobacter cloacae during the early development of mixed-in-
fection subcutaneous abscesses (39). Antimicrobial therapy
was started before bacterial inoculation to simulate the empir-
ical use of antibiotics to treat infections resulting from com-
plications following abdominal surgery. In vivo findings were
compared to the in vitro activities of the antibiotics against
mixed cultures of the strains in an anaerobic time-kill study
and to MICs determined by using standard and high inocula.
(This report was presented in part at the 2002 12th Euro-
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pean Congress of Clinical Microbiology and Infectious Dis-
eases, Milan, Italy [Clin. Microbiol. Infect. 8(Suppl. 1)56, abstr.
0388].)
MATERIALS AND METHODS
Antibiotics and media. CZX (Cefizox) was supplied by Fujisawa Holland B.V.
(Houten, The Netherlands), and injectable PIP was supplied by Bipharma B.V.
(Weesp, The Netherlands). PT was used in all in vitro and in vivo studies at a
ratio of 8:1. Pure powders of PIP monohydrate, TAZ, and injectable PT (Tazo-
cin) came from Wyeth Lederle (Louvain-la-Neuve, Belgium). Wilkens Chalgren
(WC) broth, WC agar, eosin methylene blue (EM) agar, brain heart infusion
broth (BHI), and DST agar were all supplied by Unipath Ltd. (Haarlem, The
Netherlands). Columbia blood agar plates were from Becton Dickinson B.V.
(Woerden, The Netherlands).
Bacterial strains. B. fragilis ATCC 23745 and E. cloacae clinical isolates 22491
and 032349 were used. The B. fragilis strain produced a constitutive cephalo-
sporinase that was susceptible to inhibition by clavulanic acid. The Enterobacter
strains demonstrated variations in the level of induction of their AmpC -lacta-
mase by cefoxitin (42). E. cloacae 22491 was cefoxitin inducible, and E. cloacae
032349 was less inducible. All strains were first passaged in BALB/c mice by
intraperitoneal injection of 108 to 109 CFU of overnight cultures. After 24 to
48 h, strains were recovered from the liver and spleen and cultured on blood agar
plates and standardized bacterial suspensions were made in BHI containing 20%
glycerol and stored at80°C until required. Overnight cultures were obtained by
inoculating 30-ml volumes of WC broth with 0.1 ml of the standardized frozen
bacterial suspensions and incubating them aerobically (E. cloacae) or anaerobi-
cally (B. fragilis) at 37°C for 18 h.
Animals. Female specific-pathogen-free BALB/c mice (IFFA Credo, l’Arbresle,
France) 12 to 18 weeks old and weighing 20 to 25 g were used throughout the
study. The cecal contents of male specific-pathogen-free Swiss mice (Charles
River, Maastricht, The Netherlands) were used for the production of autoclaved
cecal contents (ACC) (41). All animals received water and food ad libitum. The
study was approved by the Institutional Animal Care and Use Committee of the
Erasmus MC, Rotterdam, The Netherlands.
In vitro activity and emergence of resistance. The MICs of CZX, PIP, and PT
were determined by the standard broth microdilution method with inocula of 105
or 108 CFU/ml as previously described (41). The in vitro activities of the anti-
biotics against mixed cultures of B. fragilis and E. cloacae 22491 were measured
by the anaerobic time-kill technique outlined previously (41). Briefly, 2-ml vol-
umes of WC broth containing twofold increasing concentrations of CZX, PIP, or
PT were placed in 5-ml polypropylene tubes (Greiner B.V., Alphen a/d Rijn, The
Netherlands). Control samples contained 2 ml of WC broth alone. Tubes were
inoculated with diluted overnight cultures of B. fragilis (1 ml) and E. cloacae (1
ml) to give mixed cultures with a final volume of 4 ml containing 108 CFU of each
strain per ml. The final antibiotic concentrations were 0.125 to 512 g/ml (CZX)
and 0.125 to 2,048 g/ml (PIP and PT). The in vitro activity of CZX against
mixed cultures of B. fragilis and E. cloacae strain 032349 was similarly tested.
Cultures were incubated anaerobically at 37°C for 24 h. Cultures were washed
twice in phosphate-buffered saline (PBS), and total bacterial counts were deter-
mined by making duplicate serial 10-fold dilutions in PBS and plating 20 l of
each dilution onto EM agar (E. cloacae) or WC agar containing 100 mg of
gentamicin per liter (B. fragilis). Plates were incubated at 37°C aerobically for
24 h (EM agar) or anaerobically for 48 h (WC agar). Counts were expressed as
log10 CFU per milliliter, and the lower limit of detection was 2.5 log10 CFU/ml.
Resistant E. cloacae mutants were isolated from the same mixed cultures on WC
agar plates containing CZX, PIP, or PT at 1, 2, 4, 8, or 16 times the MIC that had
been incubated aerobically for 48 h at 37°C. To isolate B. fragilis mutants, the WC
agar plates, in addition to the CZX, PIP, and PT concentrations mentioned
above, also contained 100 mg of gentamicin per liter, which inhibited the growth
of the E. cloacae mutants. These plates were incubated anaerobically at 37°C for
72 h. Gentamicin had no synergistic or antagonistic effect on the activity of the
other antibiotics present in the agar plates. The mutation frequency was ex-
pressed as the ratio of the number of CFU of resistant colonies found to the total
number of CFU plated on the antibiotic-free agar.
Mouse model. The subcutaneous-abscess model described previously (40) was
used. Inocula were prepared by diluting overnight cultures of B. fragilis and E.
cloacae 22491 (or E. cloacae 032349) in WC broth, which were then mixed
together with ACC in a volume ratio of 1:1:2. The final inocula contained 107
CFU of B. fragilis, 107 CFU of E. cloacae, and 4 mg (dry weight) of ACC in a total
volume of 0.25 ml. Mice were injected subcutaneously in both flanks. Abscesses
were allowed to develop for 24 h, after which time mice were killed by CO2
asphyxiation and the abscesses were dissected, weighed, and homogenized in 1
ml of PBS for 10 s (Pro 200; B.V. Centraal Magazijn, Abcoude, The Nether-
lands). The resulting suspensions were used to determine the bacterial counts as
outlined above for the in vitro studies.
Antibiotic treatment and emergence of resistance in early abscess develop-
ment. The antibiotic dosing regimens used in this study were chosen to produce
a maximum effect in this model and took into consideration the short half-life,
approximately 0.2 h, of both CZX and PIP in mice (3, 26). Groups of two mice
were treated subcutaneously with total CZX doses of 6 to 1,536 mg/kg/day or PIP
or PT doses of 24 to 6,144 mg/kg/day. These total daily doses were divided into12
CZX doses of 0.5 to 128 mg/kg or PIP or PT doses of 2 to 512 mg/kg given every
2 h. Treatment was started 30 min before bacterial inoculation and was contin-
ued for 24 h. Mice inoculated with the B. fragilis-E. cloacae 032349 combination
were treated only with CZX or PT. The efficacy of the treatment was assessed by
a decrease in total bacterial counts (CFU per abscess) compared to those of
untreated controls analyzed on the same day. The number of resistant mutant
bacteria in each of the treated and untreated abscesses was determined on agar
plates containing CZX, PIP, or PT as outlined above for the in vitro studies. A
total of four abscesses per treatment group were analyzed.
Population analysis profiles. The population analysis profile (PAP) areas
under the curves (AUCs) were used as a method to indicate the frequency of
microorganisms isolated in relation to various drug MICs (45). The number of B.
fragilis and E. cloacae 22491 CFU on each antibiotic-containing plate was plotted
as a function of the concentration of CZX, PIP, or PT (GraphPad Prism version
3.0 for Windows; GraphPad Software, San Diego, Calif.). These plots were then
used to calculate the AUC that characterized the relative frequency of microor-
ganisms isolated in relation to various drug MICs. The PAP AUCs from the in
vitro study were compared to those obtained from the abscesses.
Characterization of resistant mutants. To assess the stability of the resistant
mutants isolated from each of the untreated and treated abscesses, four colonies
per treatment group were randomly selected from plates containing the highest
antibiotic concentration on which mutant cells could be cultured. After multiple
(at least five) subcultures on antibiotic-free agar, the MICs were retested by
using an inoculum of 105 CFU/ml. The total number of mutant strains evaluated
were 29 CZX-resistant E. cloacae 22491 mutants, 15 CZX-resistant E. cloacae
032349 mutants, 32 PIP-resistant E. cloacae 22491 mutants, 22 PT-resistant E.
cloacae 22491 mutants, and 24 CZX-resistant B. fragilis mutants (isolated from
abscesses with E. cloacae strain 22491). The susceptibility profiles of all Entero-
bacter mutants were determined by VITEK 2 (BioMe´rieux, Marcy l’E´toile, France)
in accordance with the manufacturer’s instructions.
The CZX-resistant E. cloacae 22491 isolates were further characterized by
determining the -lactamase activity of the mutants under cefoxitin-induced and
noninduced conditions. Overnight cultures of each of the isolates in BHI were
diluted 1:20 in 5 ml of fresh BHI and incubated with shaking at 37°C. A duplicate
set of cultures was also inoculated, and after 2 h of incubation, 10 g of cefoxitin
per ml (0.2 times the MIC) was added to induce -lactamase production. After
4 h, the bacteria were harvested from both the induced and noninduced cultures
by centrifugation at 1,500  g for 10 min at 4°C. The pellets were resuspended
in 500 l of 50 mM Tris-HCl (pH 7.4), and the -lactamase was extracted by the
lysozyme-based method outlined by Paterson et al. (31). The protein concentra-
tions of the enzyme extractions were measured by using a dye-binding assay
(Bio-Rad, Marnes la Coquette, France). Enzyme activity was measured by using
the technique of O’Callaghan described previously (29), with slight modifica-
tions. Briefly, 100 l of 1 mM nitrocefin solution was added to 100 l of the
enzyme extract and for 10 min the nitrocefin destruction was measured at a
wavelength of 490 nm (Bio-Rad model 550 microplate reader). The enzyme
activity was defined as micromoles of nitrocefin destroyed per minute per milli-
liter of added enzyme extract and calculated as follows: extinction/minute 0.1
mol of nitrocefin  10  dilution factor of enzyme extract. Enzyme specific
activity was expressed as micromoles per minute per milligram of protein.
Statistical analysis. The effect (E) of the antibiotics on the total bacterial
counts of the in vitro mixed cultures and the abscesses was expressed as the
difference, after 24 h, between the log10 CFU per milliliter (log10 CFU per
abscess) in the absence and presence of the antibiotics as described by the
equation E  (Emax  C)/(EC50  C), where Emax is the maximum observed
effect, C is the concentration (daily dose), and EC50 (50% effective dose [ED50])
is the concentration (daily dose) at which 50% of the maximum effect is reached.
The EC50 (ED50) was estimated by using nonlinear least-squares regression
techniques (GraphPad Prism version 3.0 for Windows; GraphPad Software). The
95% confidence intervals (CIs) were used to determine significant differences
between the antibiotics and between the different abscess combinations. In the
majority of cases, this simple Emax model gave a better fit than the more complex
Hill model and was therefore used for all analyses.
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RESULTS
Inoculum effect on MIC. An inoculum effect was found with
CZX, PIP, and PT against all three strains when the inoculum
was increased from 105 to 108 CFU/ml (Table 1). The 4- to
8-fold increase in the MICs of PIP and PT against B. fragilis
was noticeably lower than the 128-fold increase found with
CZX and the 32- to 256-fold increase found with all of the
antibiotics against the E. cloacae strains.
In vitro activity. The in vitro effects (log10 CFU per milliliter
reduction compared to controls) of CZX, PIP, and PT on
mixed cultures of B. fragilis and E. cloacae 22149 after 24 h of
incubation are shown in Fig. 1. The maximum decrease (Emax)
in B. fragilis and E. cloacae 22149 bacterial counts was 5.1
log10 CFU/ml. There were no significant differences between
the Emaxs of CZX, PIP, or PT against the two strains. However,
the concentrations of CZX, PIP, and PT required to produce
50% of these maximum effects (EC50) were significantly dif-
ferent (Table 2). There was a 13-fold and 40-fold respective
difference between the EC50 of CZX against B. fragilis com-
pared to those of PIP and PT (P  0.05). Against E. cloacae,
the EC50 of CZX was eightfold and fivefold lower than those
of PIP and PT, respectively. The EC50s of PIP and PT against
the two bacterial strains were similar. Interestingly, when the
EC50/MIC ratios were compared, all EC50s corresponded to
the MICs that were determined by using an inoculum of 108
CFU/ml but not to those obtained with standard inocula (Ta-
ble 2). Consistent with our previous studies, these MICs (108
CFU/ml) provided a better correlation with the in vitro activity
of the antibiotics against the mixed cultures (40).
In mixed cultures containing the same B. fragilis strain and
another E. cloacae strain (032349), the EC50 of CZX against
E. cloacae 032349 (5.9 g/ml) was significantly lower than the
EC50 for E. cloacae strain 22491 (results not shown). The EC50
of CZX against the anaerobe (152 g/ml) was similar to the
EC50 in the other mixed culture.
In vitro emergence of resistance. CZX-resistant colonies of
B. fragilis and E. cloacae 22491 were isolated from antibiotic-
FIG. 1. In vitro effects (log10 CFU per milliliter reduction compared to controls) of CZX, PIP, and PT on mixed cultures of B. fragilis ATCC
23745 and E. cloacae 22491 after 24 h of anaerobic incubation.
TABLE 1. MICs of CZX, PIP, and PT with different inocula
Bacterial strain and
inoculum (CFU/ml)
MIC (g/ml)
CZX PIP PT
B. fragilis ATCC 23745
105 1 2 1
108 128 16 4
E. cloacae 22491
105 0.25 4 4
108 64 512 256
E. cloacae 032349
105 0.125 2 2
108 4 512 256
TABLE 2. In vitro activities of CZX, PIP, and PT against mixed
cultures of B. fragilis ATCC 23745 and E. cloacae 22491
after 24 h of anaerobic incubationa
Antibiotic(s) and
bacterial strain
Emax (log10
CFU/ml)b
EC50
(g/ml)c
EC50/MIC ratiod
105 108
CZX
B. fragilis 8.0 202e 202 1.6
E. cloacae 6.1 51f 204 0.8
PIP
B. fragilis 5.5 16 8 1.0
E. cloacae 6.8 407 102 0.8
PT
B. fragilis 5.1 5 5 1.25
E. cloacae 6.6 263 66 1.0
a Parameters were calculated from the average log10 CFU per milliliter reduc-
tion in bacterial counts from two or three experiments.
b Maximum decrease in bacterial counts compared to those of control cultures
after 24 h of incubation.
c Antibiotic concentration producing 50% of the maximum effect.
d Ratios based on MICs determined with inocula of 105 or 108 CFU/ml.
e Significant difference between the EC50 of CZX (95% CI, 41 to 984) against
B. fragilis and those of PIP (95% CI, 7 to 35) and PT (95% CI, 3 to 10).
f Significant difference between the EC50 of CZX (95% CI, 21 to 125) against
E. cloacae and those of PIP (95% CI, 203 to 815) and PT (95% CI, 174 to 399).
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free control mixed cultures at a frequency of 104 to 107 on
agar plates containing CZX at up to 16 times the MIC. When
the mixed cultures were incubated with increasing CZX con-
centrations, the numbers of resistant B. fragilis mutant bacteria
remained stable (Fig. 2A). However, when exposed to a CZX
concentration of 2 g/ml, there was a 3 log10 CFU/ml increase
in the number of CZX-resistant E. cloacae 22491 mutant bac-
teria isolated on all antibiotic plates. With concentrations of 2
to 64 g/ml, the mutant frequency increased to 101 to 103.
No CZX-resistant mutant bacteria were isolated from cultures
containing 128 g/ml. PIP-resistant mutant bacteria were
isolated from control cultures after 24 h of incubation at a
frequency of 104 to 107 (E. cloacae 22491) and 102 to 106
(B. fragilis) on plates containing up to eight times the MIC.
Increasing PIP concentrations did not affect the total numbers
of resistant mutants recovered, although with concentrations
of 4 g/ml, resistant B. fragilis colonies were not detected on
plates containing more than the MIC (Fig. 2B). In mixed
cultures incubated with PT, the mutant frequencies of PT-
resistant E. cloacae 22491 were not significantly different from
those of PIP-resistant E. cloacae 22491; however, PT-resistant
B. fragilis mutants were completely suppressed (Fig. 2C).
In contrast to the mixed cultures with E. cloacae 22491
reported above, increasing CZX concentrations did not pref-
erentially select resistant mutants of E. cloacae 032349 from
mixed cultures with B. fragilis (results not shown).
In vivo efficacy. Similar to the in vitro study, sigmoid dose-
response curves showing the effect (log10 CFU per abscess
reduction compared to controls) of CZX, PIP, and PT in early
abscess development were created (not shown). Compared to
untreated control abscesses, there was a 5.0 log10 CFU per
abscess maximum reduction (Emax) in the bacterial counts of
both strains after 24 h of treatment with all of the antibiotics
tested (Table 3). Comparable doses of PIP and PT were re-
quired to reach the ED50 for E. cloacae strain 22491. Interest-
ingly, the ED50 of CZX against E. cloacae 22491 was similar to
those of PIP and PT. There was, however, a significant ninefold
and fivefold respective difference between the ED50 of PT
against B. fragilis and those of CZX and PIP against the anaer-
obe (P  0.05).
To determine whether the antibiotics would have a similar
bactericidal effect against another clinical isolate of E. cloacae,
abscesses containing mixed infections of the same B. fragilis
strain with E. cloacae 032349 were also treated with CZX or
PT (Table 3). The Emaxs of both antimicrobials were compa-
rable to those found in the other mixed infection. However,
compared to E. cloacae 22491, a significant 25-fold lower dose
of CZX was required to reach the ED50 for E. cloacae 032349
(P  0.05). Furthermore, the ED50 of CZX against B. fragilis
was significantly 10-fold lower when the anaerobe was in the
mixed infection with E. cloacae 032349 (P  0.05). The ED50s
of PT against the two E. cloacae strains were similar, as were
the ED50s of PT against the B. fragilis strain in both abscess
combinations.
Consistent with the in vitro study, MICs obtained with the
higher inocula correlated better with in vivo activity than did
standard MICs. When the ED50/MIC ratios (inocula of 10
8
CFU/ml) of the two combinations were compared, similar ra-
tios were found between the two Enterobacter strains with both
CZX and PT (Table 3). Similarly, all of the PIP and PT ratios
of B. fragilis in both abscess combinations were comparable
although they were 4- or 30-fold higher than those of CZX.
This may have been due to the higher protein binding of PIP
in vivo compared to that of CZX (6, 12, 26) and was more
apparent with the anaerobe owing to the lower MIC (high
inoculum) compared to that for the Enterobacter strains. The
CZX ratios of B. fragilis in the two mixed infections differed
10-fold.
Emergence of resistance in early abscess development.
CZX-resistant mutants were isolated from untreated control
B. fragilis-E. cloacae 22491 abscesses 24 h after inoculation at a
frequency of 103 to 106 for both strains on plates containing
drug concentrations of up to 16 times the MICs (Fig. 3A). With
increasing doses of CZX, the numbers of resistant B. fragilis
colonies remained stable. However, with doses of 12 to 96
mg/kg/day, there was an increase, up to 1,000-fold, in the num-
ber of CZX-resistant E. cloacae bacteria, with almost all sus-
ceptible bacteria being replaced by resistant mutants. No
CZX-resistant mutants were cultured from abscesses treated
with CZX at 	768 mg/kg/day. PIP resistance occurred in un-
treated B. fragilis-E. cloacae 22491 mixed infections at frequen-
cies of 104 to 108 on plates containing PIP at two to four
times the MIC (Fig. 3B). The B. fragilis mutant frequency was
unaffected by increasing PIP doses. However, with doses of 192
to 1,536 mg/kg/day, there was an increase in the degree of
resistance of the E. cloacae mutants recovered since they could
also be isolated on plates containing PIP at 8 and 16 times the
MIC. PT-resistant E. cloacae 22491 mutants were isolated at a
frequency of 105 to 106 on plates containing PT at up to four
times the MIC (Fig. 3C). Increasing PT doses did not alter this
frequency. B. fragilis mutants were not isolated on plates con-
taining PT at concentrations greater than the MIC.
In B. fragilis-E. cloacae 032349 mixed infections, the number
of CZX-resistant E. cloacae mutants isolated from untreated
abscesses 24 h after inoculation was markedly lower than that
of CZX-resistant E. cloacae mutants cultured from the mixed
infections with E. cloacae 22491 (Fig. 4A). These mutant num-
bers were reduced even further by increasing CZX doses. The
mutant frequencies of CZX-resistant B. fragilis mutants in both
untreated and treated abscesses were similar in both abscess
combinations. However, compared to the B. fragilis-E. cloacae
22491 abscesses, there was an eightfold reduction in the total
daily doses of CZX at which resistant cells of both E. cloacae
and B. fragilis could no longer be isolated, i.e., 	96 mg/kg/day
versus 	768 mg/kg/day. Very few PT-resistant E. cloacae
032349 bacteria and no PT-resistant B. fragilis bacteria were
isolated from untreated and PT-treated abscesses on plates
containing PT concentrations greater than the MIC (Fig. 4B).
Comparison of in vitro and in vivo PAP AUCs. The effects of
the antibiotics on bacterial populations recovered from ab-
scesses were compared to those on bacteria isolated from in
vitro mixed cultures. Figure 5 shows that the in vitro profiles of
both B. fragilis and E. cloacae 22491 were very similar to those
found in vivo with each respective antibiotic. In all instances, B.
fragilis behaved differently from the E. cloacae strain; the PAP
AUCs of the anaerobe decreased with increasing antibiotic
concentrations, while those of E. cloacae remained more sta-
ble. Furthermore, the superior effect of PT compared to those
of CZX and PIP on the population profiles of the resistant
B. fragilis mutants is evident.
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FIG. 2. In vitro effects of increasing concentrations of CZX, PIP, or PT on the emergence of resistant mutants from mixed cultures of B. fragilis
ATCC 23745 and E. cloacae 22491 after 24 h of anaerobic incubation. The effects of the antibiotics on the total bacterial counts were determined
on antibiotic-free media (0). Resistant mutants were isolated on agar plates containing CZX, PIP, or PT at 1, 2, 4, 8, or 16 times the MIC.
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Stability and susceptibility profiles of resistant mutants.
After multiple subcultures on antibiotic-free agar, all B. fragilis
mutants and one E. cloacae 22491 mutant isolated on plates
containing CZX at 8 to 16 times the MIC were unstable, with
the MICs of the cephalosporin for these mutants being the
same as those for the parent strains. However, 28 of the 29
CZX-resistant E. cloacae 22491 mutants isolated from un-
treated or CZX-treated abscesses were stable after multiple
subcultures, with 8- to 512-fold increases in the MICs for the
mutants (inoculum, 105 CFU/ml) compared to that for the
parent strain. The susceptibility profiles of the parent strain
and the CZX-resistant mutants were determined by VITEK 2.
The parent strain and mutants were all susceptible to the
aminoglycosides, quinolones, sulfonamides, and carbapenems
tested and resistant to amoxicillin-clavulanic acid, ampicillin,
and narrow- and extended-spectrum cephalosporins. However,
the CZX-resistant mutants differed from the parent strain in
their susceptibility to broad-spectrum cephalosporins, as well
as PIP and PT. On the basis of their susceptibilities to these
antibiotics and independent of whether they were isolated
from an untreated abscess or from any of the treated abscesses,
the mutants could be divided into two groups with differing
profiles (Table 4). Fifty percent of the isolates for which the
MICs of CZX were 32 to 128 g/ml (group A) had an inter-
mediate susceptibility to PT and were resistant to PIP and all
of the broad-spectrum cephalosporins tested, except for
cefepime. The group B mutants (CZX MICs of 2 to 64 g/ml)
were resistant to cefpodoxime and susceptible to all of the
other antibiotics.
The PT-resistant E. cloacae 22491 mutants (n 22) could be
similarly divided into groups with differing susceptibility pro-
files. Thirty-two percent of the mutants were unstable after
subculture and had the same profile as the parent strain, while
32 and 36%, respectively, had profiles similar to those in groups
A and B in Table 4 (excluding CZX). Likewise, the PIP-re-
sistant E. cloacae 22491 mutants (n  32) could be categorized
as unstable (19%), group A (41%), or group B (41%). Inter-
estingly, the group A mutants were only isolated from ab-
scesses treated with PIP at 192 to 1,536 mg/kg/day.
In contrast to E. cloacae 22491, E. cloacae 032349 was sus-
ceptible to all of the antibiotics tested, except cefalotin and
cefuroxime. After subculture, the CZX MIC for the CZX-re-
sistant E. cloacae 032349 mutants (n 15) was either the same
as or two- to fourfold higher than that for the parent strain.
When examined by VITEK 2, 60% of the mutants had the
same susceptibility profile as the parent strain and 40% were
resistant to cefoxitin and ampicillin and had intermediate sus-
ceptibilities to cefpodoxime (results not shown).
-Lactamase activities of CZX-resistant E. cloacae 22491
mutants. The CZX-resistant E. cloacae 22491 mutants were
further characterized by determination of their -lactamase
activities in the presence (induced) or absence (noninduced) of
cefoxitin. Under normal noninduced conditions, the parent
strain produced low-level -lactamase activity (Table 5). This
enzyme level could be increased 10-fold by induction with
cefoxitin. The CZX-resistant mutants could be further divided
according to their -lactamase activities. In susceptibility pro-
file group A, six mutants (for all of which the CZX MIC was
128 g/ml) produced very high enzyme levels that could not be
increased by induction, indicating that these were stably dere-
pressed mutants. Seven of the group A mutants also produced
higher base levels of the enzyme than the parent strain but
could still be induced by cefoxitin. These mutants could be
regarded as partially derepressed. Susceptibility profile group
B mutants could be similarly divided into mutants that were
stably (n  4) or partially (n  4) derepressed, albeit with
lower enzyme activity than those of group A. Seven isolates
(group A, n 1; group B, n 6) had an enzyme activity similar
to that of the parent strain despite the fact that the CZX MICs
for these isolates were 8- to 256-fold higher. This suggests that
resistance mechanisms other than -lactamase production might
play an important role in the resistance of these mutants to CZX.
DISCUSSION
In this B. fragilis-E. cloacae subcutaneous mixed-infection
abscess model, we have shown that treatment with PT can
suppress the selection of resistant mutants of both the E. clo-
acae and B. fragilis strains during early abscess development. In
contrast to PT, the importance of antibiotic doses for the
selection of CZX-resistant E. cloacae has been clearly demon-
strated. This has not been widely reported previously; indeed,
the authors are unaware of any studies with an in vivo model
that have so thoroughly documented this adverse aspect of
TABLE 3. In vivo efficacies of CZX, PIP, and PT against different
B. fragilis ATCC 23745-E. cloacae mixed infections
in early abscess developmenta
Mixed infection
and antibiotic Bacterium
Emax
(log10 CFU/
abscess)b
ED50
(mg/kg/
day)c
ED50/MIC
ratiod
105 108
B. fragilis-E. cloacae
22491
CZX B. fragilis 7.5 771 771 6
E. cloacae 8.4 521 2,084 8
PIP B. fragilis 5.9 416 208 26
E. cloacae 5.0 643 161 1.3
PT B. fragilis 6.1 85e 85 21
E. cloacae 6.1 554 139 2.2
B. fragilis-E. cloacae
032349
CZX B. fragilis 5.5 81f 81 0.6
E. cloacae 7.6 21g 168 5
PT B. fragilis 5.7 77 77 19
E. cloacae 5.2 766 383 3
a Treatment (CZX every 2 h at 6 to 1,536 mg/kg/day or PIP or PT every 2 h at
24 to 6,144 mg/kg/day) was started 30 min before inoculation and continued for
24 h. Parameters were calculated from the average log10 CFU per abscess
reduction in bacterial counts of four abscesses.
b Maximum decrease in abscess bacterial counts after treatment for 24 h
compared to those of untreated control abscesses.
c Daily dose of antibiotic producing 50% of the maximum effect.
d Ratios based on MICs determined with inocula of 105 or 108 CFU/ml.
e Significant difference between the ED50s of PT (95% CI, 44 to 166) against
B. fragilis and those of CZX (95% CI, 314 to 1,892) and PIP (95% CI, 180 to 961)
against the anaerobe in the E. cloacae 22491 combination.
f Significant difference between the ED50s of CZX against B. fragilis in the E.
cloacae 22491 (95% CI, 314 to 1,892) and E. cloacae 032349 (95% CI, 46 to 143)
abscess combinations.
g Significant difference between the ED50 of CZX against E. cloacae 032349
(95% CI, 13 to 34) and the ED50 of PT (95% CI, 421 to 1,394) and those of CZX
(95% CI, 228 to 1,188) and PT (95% CI, 207 to 1,485) against E. cloacae strain
22491.
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FIG. 3. Effects of CZX, PIP, or PT doses on the emergence of resistant strains of B. fragilis ATCC 23745 and E. cloacae 22492 in early abscess
development. Treatment (CZX every 2 h at 6 to 1,536 mg/kg/day or PIP or PT every 2 h at 24 to 6,144 mg/kg/day) was started 30 min before
inoculation and continued for 24 h. Total bacterial counts were determined on antibiotic-free media (0), and those of resistant mutants were
determined on agar plates containing CZX, PIP, or PT at 1, 2, 4, 8, or 16 times the MIC.
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expanded-spectrum cephalosporin therapy in comparison to
treatment with a -lactam–-lactamase inhibitor combination
(19, 21, 23, 28, 32). Furthermore, the resistant mutants selected
during therapy comprised a heterogeneous population of not
just stably derepressed mutants, as previously reported, but
also mutants with resistance mechanisms other than -lacta-
mase production (4, 17, 34).
Although broad-spectrum cephalosporins should be avoided
as primary agents against Enterobacter strains (8) and CZX
would not be considered the most useful antianaerobic agent,
broad-spectrum cephalosporins are still advised for empirical
use against mixed infections (7). Furthermore, and despite
recommendations to the contrary, expanded-spectrum cepha-
losporins are still widely used in many countries for surgical
prophylaxis (16, 36). The murine model used in this study
simulates the clinical situation in which PT or an expanded-
spectrum cephalosporin would be empirically used to treat an
infection resulting from complications following abdominal
surgery, such as leakage of an intestinal suture (7). In this case,
antibiotic treatment has to be started prior to reoperation.
Since preoperative prophylaxis with a narrow-spectrum ceph-
alosporin is standard practice in abdominal surgery (15, 16),
FIG. 4. Effects of CZX or PT doses on the emergence of resistant strains of B. fragilis ATCC 23745 and E. cloacae 032349 in early abscess
development. Treatment (CZX every 2 h at 6 to 1,536 mg/kg/day or PT every 2 h at 24 to 6,144 mg/kg/day) was started 30 min before inoculation
and continued for 24 h. Total bacterial counts were determined on antibiotic-free media (0), and those of resistant mutants were determined on
agar plates containing CZX, PIP, or PT at 1, 2, 4, 8, or 16 times the MIC.
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there is a risk that these intraabdominal infections could in-
volve Enterobacter strains unaffected by the antibiotic prophy-
laxis. Although antibiotic therapy is an adjunctive treatment
for surgical abscess drainage, small undrainable intraabdomi-
nal abscesses could also develop.
Definite antibiotic therapy is chosen on the basis of in vitro
susceptibility tests with low inocula (24). However, the present
study has demonstrated the importance of using high inocula
to identify the potential of an antibiotic to select resistance to
itself and other antibiotics and to predict its in vivo efficacy in
infections involving high bacterial numbers (38, 40, 44). In
standard MIC tests with inocula of 105 CFU/ml, both the
Enterobacter and B. fragilis strains would be regarded as sus-
ceptible to CZX, PIP, and PT (27), and yet differing antibac-
terial activities were found against mixtures of these strains
both in vitro and in vivo. However, there was a good correla-
tion between in vitro and in vivo efficacy and the MICs ob-
tained with a higher inoculum. These results corroborate the
findings of Soriano et al. (38), who also reported a better
correlation of the in vivo efficacies of five different -lactams in
a murine E. coli infection model with the MICs of the antibi-
otics obtained with high inocula. Although there are several
rigorous environmental conditions that could limit the activity
of an antibiotic in abscesses, e.g., pH, anaerobiosis, and cell
FIG. 5. Comparison of the in vitro and in vivo effects of CZX, PIP, and PT on the PAPs of B. fragilis and E. cloacae 22491 recovered from mixed
cultures and mixed-infection abscesses. The PAP AUCs of bacteria recovered from plates containing each drug at 0, 1, 2, 4, 8, or 16 times the MIC
are shown.
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debris (22), the present study emphasizes how important the
presence of high bacterial numbers can be to antibiotic efficacy
(41). All EC50s corresponded to the higher MICs, and in vivo,
low MICs were associated with lower ED50s. In both abscess
combinations, the ED50s of CZX against all of the strains
tested corresponded to the doses used when no or few resistant
mutants were isolated from the mixed infections. The inferior
in vivo killing of the anaerobe by CZX in E. cloacae 22491
abscesses compared to that in the E. cloacae 032349 combina-
tion may, in part, be due to hydrolysis of the antibiotic by the
high -lactamase concentrations produced by the resistant En-
terobacter cells. Consequently, it appeared that the preferential
selection of resistant mutants of one strain had compromised
the efficacy of the antimicrobial against another member of the
mixed infection. These findings indicate, therefore, that the
problem of emergence of resistance during -lactam therapy
may be further compounded when the infections being treated
comprise different bacterial strains. This phenomenon, how-
ever, may not be confined to -lactams since we have also
found that the in vitro and in vivo activities of a fluoroquino-
lone against the B. fragilis strain were similarly affected by the
nature of the bacterial strain coexisting in the mixed culture
(infection) (40, 41).
The results presented here confirm that TAZ can potentiate
the activity of PIP against B. fragilis, as shown by the reduced
MICs, EC50s, ED50s, and PAP AUCs (2, 18, 33), but does not
enhance the activity of PIP against the two E. cloacae strains
(1, 33). However, TAZ does appear to play an important role
in the suppression of resistance to PIP in both the Enterobacter
and B. fragilis strains (19, 20). Although TAZ is a highly active
inhibitor of the -lactamase of B. fragilis (2, 18, 33), its activity
against the AmpC -lactamase of E. cloacae is limited (1).
Nevertheless, TAZ seems to have some ability to potentiate
the activity of PIP against derepressed mutants of E. cloacae
(1). It has been suggested that suppression of resistance by PT
is mediated by the inhibition of the AmpC -lactamase of a
subpopulation of moderately resistant mutants of E. cloacae
(20). In this study, we have verified that during treatment with
selective doses of PIP (192 to 1,536 mg/kg/day), E. cloacae
mutants with a high degree of resistance to PIP can be sup-
pressed by TAZ.
CZX-resistant B. fragilis mutants were isolated from un-
treated abscesses at a frequency similar to that of E. cloacae
strain 22491, but these were not preferentially selected during
treatment with the cephalosporin. Furthermore, it appeared
that the resistance character of these strains could be lost by
multiple subcultures on antibiotic-free agar. Resistance to
-lactams in anaerobic bacteria is attributed primarily to the
constitutive production of high levels of -lactamase (10). In a
recent in vitro study, it was demonstrated that resistant Bacte-
roides strains selected with the cephalosporin cefoxitin dis-
played no enhanced -lactamase activity compared to that of
the parent strain but did have altered penicillin-binding pro-
teins and outer membrane proteins (14). In addition, this re-
sistance was lost after multiple subcultures on antibiotic-free
agar, indicating that the alterations were only produced under
antibiotic pressure. The resistant Bacteroides mutants isolated
in the present study were not further characterized. Neverthe-
less, owing to their unstable character, it is possible that their
initial resistance to CZX was mediated by a non--lactamase
resistance mechanism.
In conclusion, the present animal model demonstrates the
adverse microbiological outcome of choosing an expanded-
spectrum cephalosporin such as CZX for the empirical treat-
ment of mixed infections in which a susceptible Enterobacter
strain could be present. Importantly, the selection of these
resistant mutants was apparent within 24 h of treatment and
was dose dependent. This preferential selection was not found
after treatment with PT. In addition, our study confirms that
clinicians could be misled by results of standard susceptibility
tests of isolates from intraabdominal infections.
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